In this study, it was revealed that newly diagnosed asymptomatic cancer patients are frequently associated with metastatic bone disease, those can be detected by bone scintigraphy.
INTRODUCTION
Cancer is an important cause of morbidity and mortality in Bangladesh. The estimated incidence of 12.7 million new cancer cases worldwide in 2008 will rise to 21.4 million by 2030 (1) . Metastases to bone is common than primary bone malignancies and it is the third most common organ affected by metastasis, after the lungs and liver (2) . Almost all types of cancer may metastasize to bone. But metastases from carcinomas are the most common, particularly those arising in the following areas-breast, lung, prostate, kidney, thyroid (3).
Bone metastases most commonly affect the axial skeleton, which contains the red marrow in the adult. The vertebrae, pelvis, ribs and the ends of long bones are most common sites of metastases because of their high red marrow content. Within the spine, 52% metastases are located in the lumbar spine, 36% are located in the thoracic spine and 12% are located in the cervical spine. Mandible, patella and distal extremities are the less frequent metastatic sites (2).
Many metastatic bone lesions cause no symptom. The presentation of metastatic bone disease is variable, but pain is the most common complaint. Other clinical feature includes-hypocalcaemia, pathological fracture and neurological symptoms due to compression of the spinal cord or cauda equine and spinal instability. Complication of bone metastases are referred as "skeletal related events". The occurrence of these morbid events is not regular, and becoming more frequent as the disease becomes more extensive and the treatment options reduce (4) . Therefore, early detection of bone metastases is essential for (i) accurate staging and optimal treatment; and (ii) to allow selecting suitable treatment strategies to reduce the risk of complications and improve quality of life (2) .
In NINMAS, bone scintigraphy is being done for decades. A good number of cancer patients are sent to NINMAS by the clinicians for bone scintigraphy for baseline staging and follow up. But sometimes asymptomatic cancer patients may remain undiagnosed due to social condition and lack of widespread facility. In this regard, more care needs to be taken for diagnostic procedure for the sake of the wellbeing of the patients, especially the asymptomatic cancer patients. Only a few studies have been undertaken in this institute prospectively to evaluate the role of bone scintigraphy in newly diagnosed asymptomatic cancer patients. Therefore, this prospective observational study was designed to assess the utility of bone scintigraphy in detecting metastases in newly diagnosed cancer patients as baseline investigation, who were asymptomatic for bone metastases.
PATIENTS AND METHODS
This cross sectional observational type of study was carried out at NINMAS, BSMMU campus, Dhaka during the period of July 2015 to June 2016. Newly diagnosed asymptomatic cancer patients referred to the institute (NINMAS) for the first time bone scan were included in this study. A total of 116 patients were enrolled in this study. All the patients were informed of the potential risks and benefit of the procedure and informed consent was taken from each individual case before inclusion in the study. Details of the history were obtained on the data collection sheet.
Bone scintigraphy was performed with 99mTc Methylene diphosphonate (MDP) given intravenously at a dose of 555-740MBq (15-20 m Ci). Imaging was done 2-3 hours after tracer injection by a dual head gamma camera using low energy, high resolution collimator. The whole body bone scanning was accomplished by obtaining anterior and posterior views. Additional views were taken where necessary to define the location and extent of any questionable abnormality. Interpretation done by experienced nuclear medicine physician and abnormalities (area of increased or decreased tracer localization) were recorded according to number, anatomical location and distribution (focal or diffuse). Bone biopsy, the confirmatory investigation for bone metastases, was not done due to unavailability and the skeletal lesions were considered as metastatic and non-metastatic according to the opinion of nuclear medicine experts.
The collected data were compiled and analyzed using window based computer software MS Excel and Statistical Package for Social Sciences (SPSS-16) by appropriate statistical methods. Continuous data were presented as mean and standard deviation (SD). Categorical/qualitative data were presented as percentage (%). Chi-Square test was used to analyze the variable. Level of significance was 0.05 and pvalue ≤ 0.05 was considered as significant. Various tables were used for data presentation.
RESULTS
Total 116 patients (M-57, F-59) age ranging from 20-89 years (mean ± SD = 54.8 ± 14 years) were included ( 20(66.7%) had positive bone scan and 10(33.3%) had negative bone scan. Carcinoma prostate and carcinoma breast had significantly (P < 0.05) higher and significantly (P < 0.05) lower positive bone scan findings, respectively (Table 6 ). Among the 52 patients, majority (57.7%) patients had rib as metastatic site. Hip bone and lumbar vertebra had same frequency (32.7%) as metastatic site. Fourteen (26.9%) patients had thoracic vertebra as metastatic site (Table 5 ). (5) . In this present study it was observed that 44.8% asymptomatic cancer patients were found to have positive metastatic lesions on bone scan. This study finding differ from study done by Embati (2015) , who found 81.6% metastatic lesions in symptomatic patients and 88.9% in asymptomatic patients (6) . This discordance may be due to the total number of patients (n = 1575) in his study. Moreover, he included all types of cancer patients, symptomatic, asymptomatic and treated and untreated.
In this study, 52 out of 116 patients had metastatic lesions detected by bone scan. Among the 52 patients, majority (57.7%) patients had rib as metastatic site. Hip bone and lumbar vertebra had same frequency (32.7%) as metastatic site followed by thoracic vertebra (26.9%), then sternum and skull (23.1%). Rusu, et al. (2004) found the higher frequency of metastasis was in the vertebral column, then the pelvis, rib and sternum (7) . Similarly Fallahi, et al. (2011) reported the most common sites of skeletal metastases in the different types of cancer were vertebral column, pelvis, sternum and rib, respectively (8) . These findings were in disagreement with the current study may be due to variation in the type of cancer and number of patients.
In this current study, it was observed that among asymptomatic carcinoma breast patients 21.7% patients had positive bone scan for metastatic disease. Fallahi, et al. (2011) found 58.5% of patients with bone metastasis due to breast cancer reported no localized bone pain which was higher than the current study (8) . This current study also revealed that 20(66.7%) out of 30 asymptomatic carcinoma prostate patients found positive for bone metastases detected by bone scan. Fallahi, et al. (2011) found no significant association between the site of bone metastases and location of the pain perception in most of the skeletal zones in the subgroup with prostate cancer (8). Moslehi, et al. (2012) found out of 203 asymptomatic patients with prostate cancer, 55 cases (27.1%) had bone metastasis which was lower than the current study (9) . Levren, et al. (2011) examined the relationship between bone pain and metastases in a group of patients with prostate or breast cancers (10) . They found that 47% (18 out of 38) patients with prostate cancer with pain and 12% (2 out of 17) patients without pain had metastasis. On the other hand, in the subgroup of breast cancer, 71% of the asymptomatic patients had metastasis and 34% of the patients with pain had metastases. They concluded that there was a significant association between pain and skeletal metastases in patients with prostate cancer and a reverse relationship in patients with breast cancer (10) . But in this current study prostate cancer patients without pain had higher frequency of metastatic bone disease detected by bone scan than the patients of breast cancer without pain. In the subgroup with lung cancer, in this study it was observed that among 12 patients, 8(66.7%) patients had positive bone scan. Shinto, et al. (2009) (13) . These findings were in disagreement with the current study may be due to insufficient number of cases and inclusion of all types of lung cancer in the current study.
Limitations of the study are that the study population was selected from one tertiary referring hospital in Dhaka city, so that the results of the study may not reflect the exact incidence of the country and the present study was conducted at a very short period of time. Small sample size was also a limitation of the present study.
In future, multicentre study may be done and further studies may be undertaken by including large number of patients. Bone scintigraphy may be done in newly diagnosed asymptomatic cancer patients as baseline investigation for the initial staging of disease and proper management of patients.
CONCLUSION
Bone scan finding was positive in 44.8% newly diagnosed asymptomatic cancer patients. Among the most common two types of cancer, frequency of skeletal metastatic lesion detected by bone scan was higher in asymptomatic prostate cancer patients than asymptomatic breast cancer patients, but skeletal metastatic lesion was found in almost all type of cancer patients without metastatic symptoms. It may be concluded from the results of present study that newly diagnosed asymptomatic cancer patients are frequently associated with metastatic bone disease, those can be detected by bone scintigraphy. Clinicians may consider bone scan as baseline investigation in the asymptomatic cancer patients for initial staging and planning for treatment.
